Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids

NCT05946135 | Completed Phase 4

• 1 other identifier: 4-2023-0598
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

• This clinical trial is conducted as a double-blind, randomized, and active drug control clinical trial. If the screening results determine that the selection/exclusion criteria are met, the clinical trial drugs are randomly assigned at a 1:1 ratio of the Pexuprazan 40 mg and the Lansoprazole 15 mg dose group and taken for 4 weeks.
• Gastritis symptoms are evaluated four weeks after baseline (Visit1) and clinical drug administration (Visit2), and if it is determined that gastritis is necessary according to the medical team's judgment due to gastrointestinal symptoms during the study participation period, endoscopy is performed to check whether gastritis occurs.

Conditions

Patients on Treatment With Systemic Steroids

Outcome Measures

Primary Outcomes (1)

• Changes in baseline gastritis symptoms based on gastritis symptom index at 4 weeks

  To evaluate the effect of preventing gastritis symptoms, changes in gastritis symptoms using gastritis symptom index after 4 weeks compared to baseline were compared. The gastritic symptoms index consisted of 10 items to be questioned about the frequency and degree of symptoms over the past 4 weeks.

  baseline and 4 weeks later

Study Arms (2)

Control

ACTIVE COMPARATOR

lansoprazole + placebo for Fexuprazan Hydrochloride

Drug: Lansoprazole

Intervention

EXPERIMENTAL

placebo for lansoprazole + Fexuprazan Hydrochloride

Drug: Fexuprazan Hydrochloride

Interventions

Lansoprazole DRUG

taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks

Control

Fexuprazan Hydrochloride DRUG

taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks

Intervention

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A person who voluntarily signed a consent form
• Adult men and women over 20 years of age
• Patients who require systemic steroid treatment of at least 4 weeks of moderate dose (20 mg/day or more based on prednisolone) due to respiratory diseases during screening
• Patients who are already on steroids can also participate (If there is a gastric protective agent in use, patients should agree to replace it with clinical trial drug)
• Patients who satisfy both of the following in relation to the evaluation index of gastritis symptoms during screening
• \- Gastritis symptom frequency indicator: 5 points or less
• \- Gastritis symptom intensity indicator: 5 points or less
• A person who has at least one of the following risk factors for gastric ulcer during screening
• ① Long-term use of NSAIDs for longer than 12 weeks (NSAIDs should be maintained continuously during the clinical trial.)
• ② A person who has a history of peptic ulcer in the past
• ③ 50 years of age or older
• ④ In combination with low-dose aspirin (aspirin 325 mg/day or less) (Low-dose aspirin should be maintained continuously during the clinical trial.)
• A person who understand and follow the guidance of the research manager according to the research plan, and who can participate whole period of clinical trial

You may not qualify if:

• A person who has a hypersensitivity reaction to the components of this clinical trial drug or benzimidazole-based drug or has a history of clinically significant hypersensitivity reaction
• A person who has undergone surgery that may affect gastric acid secretion, such as upper gastrointestinal resection, gastric acid secretion inhibition surgery, and gastric mucosal resection
• Those who have a history of gastrointestinal malignancies within 5 years of screening (excluding after endoscopic resection of gastric carcinoma or early gastric cancer)
• Patients with Barrett's esophagus (over 3 cm), gastroesophageal varices, esophageal stenosis, ulcer stenosis, active peptic ulcers, and acute gastrointestinal bleeding
• Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, etc.), irritable bowel syndrome (IBS), primary esophageal motility disorder, and pancreatitis
• Patients with eosinophilic esophagitis (if the esophageal biopsy determines that it is not eosinophilic esophagitis, they can participate)
• Those who have a history of gastric acid secretion disorders such as Zolinger-Elison syndrome
• A person who is currently confirmed positive for Helicobacter pyrroly infection
• Persons taking medications contraindicated to clinical trial drug (e.g., atazanavir, nelfinavir, or rilpivirine-containing agents)
• Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose absorption disorder
• Patients with severe renal and liver disorders according to the physician's judgment
• A person who disagrees with the appropriate use of contraception by himself/herself or his/her partner during the clinical trial period
• Pregnant women or breast feeding women
• Any person who has any clinical findings that are deemed medically inappropriate for this trial under the judgment of the research manager

Sponsors & Collaborators

• Yonsei University: lead

Study Sites (1)

Severance Hospital

Seoul, South Korea

Location

MeSH Terms

Interventions

Lansoprazole

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Ji Ye Jung

  Severance Hospital, Division of Pulmonary and Critical Care Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2023
• First Posted: July 14, 2023
• Study Start: November 7, 2023
• Primary Completion: September 8, 2025
• Study Completion: September 8, 2025
• Last Updated: January 13, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)